CicloMed LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.ciclomed.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- CicloMed LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04956042
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸John Hopkins School of Medicine, Baltimore, Maryland, United States
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- CicloMed LLC
- Target Recruit Count
- 9
- Registration Number
- NCT04608045
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- CicloMed LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04525131
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: CPX-POM - 600 mg/m^2Drug: CPX-POM - 30 mg/m^2Drug: CPX-POM - 360 mg/m^2Drug: CPX-POM - 1200 mg/m^2Drug: CPX-POM - 240 mg/m^2Drug: CPX-POM - 60 mg/m^2Drug: CPX-POM - 120 mg/m^2Drug: CPX-POM - 900 mg/m^2
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- CicloMed LLC
- Target Recruit Count
- 19
- Registration Number
- NCT03348514
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
News
No news found